Reporting on this terrible pandemic for Nature @naturenews and former fellow @KSJatMIT. Views are my own. She/her. Email: amy.maxmen at us.nature. com.
🧐 My latest investigation looks at US' lagging surveillance for variants.
“We have enough sequencers to sequence SARS-CoV-2 from every case, 100x over,” @K_G_Andersen told me.
But we are sequencing just 1.5% of cases, according to @GISAID posts.
... meanwhile.. why should @dmaccannell fund university labs to sequence SARS-CoV-2? When he pays your tax dollars to @Labcorp et al, he is senior author on all the sequences they deposit in GenBank & @GISAID .. probably 50,000 by now. pic.twitter.com/J84GAFmcNl
Just one example of what the AUTHORSHIP on these sequences you tax $$ are paying for look in GISAID.. why would @dmaccannell or the office he is CHIEF SCIENTIST of want to fund me or any other academic lab to sequence in Louisiana? pic.twitter.com/aOScvjHSoQ
@macroliter I normally don’t feed the trolls. The authors listed here pull together tens of thousands of samples and sequences each week from all over the country. Their efforts are significant, and recognition is completely appropriate. Publications have little bearing on federal employment
Genomic surveillance is an important issue, one that is playing out in many countries at the moment. Only a few countries have really good virus-sequencing operations; there are logistical problems & even the US can't get its act together...1/n
New @amymaxmen article in @NatureNews chronicles the challenges of variant surveillance:
- most COVID-19 tests are done by diagnostic labs that frequently discard samples after testing
- the fragmented US health system makes coordination a difficult